Activation of the mTOR pathway occurs in a substantial number of advanced-stage urothelial carcinomas; for this reason, a phase I study was conducted in patients with advanced-stage tumours to investigate the combination of the mTOR inhibitor everolimus with gemcitabine and split-dose cisplatin. Treatment with this combination resulted in haematological toxicities at the lowest dose in one of three patients during the first treatment cycle, and in all patients receiving a moderate dose of everolimus. This rapid emergence of haematological toxicities precludes further use of this treatment regimen.
References
Abida, W. et al. Phase I study of everolimus in combination with gemcitabine and split-dose cisplatin in advanced urothelial carcinoma. Bladder Cancer http://dx.doi.org/10.3233/BLC-150038 (2016)
Rights and permissions
About this article
Cite this article
Sidaway, P. Novel chemotherapy triplet for advanced UC. Nat Rev Urol 13, 125 (2016). https://doi.org/10.1038/nrurol.2016.19
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.19